• Biosimilar Hyrimoz^® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
• Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
• Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division …

• Net sales grew 5% (cc[1], +7% USD) mainly driven by:
  • Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU
  • Entresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwide
  • Oncology grew 10% (cc) driven by continued growth from Promacta/Revolade, Tafinlar + Mekinist and Jakavi, uptake of Kisqali and Kymriah and contribution from the AAA acquisition
• Core[ …